284 related articles for article (PubMed ID: 26491664)
21. Chronic NOS inhibition accelerates NAFLD progression in an obese rat model.
Sheldon RD; Padilla J; Jenkins NT; Laughlin MH; Rector RS
Am J Physiol Gastrointest Liver Physiol; 2015 Mar; 308(6):G540-9. PubMed ID: 25573175
[TBL] [Abstract][Full Text] [Related]
22. The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease.
Ferolla SM; Armiliato GN; Couto CA; Ferrari TC
Nutrients; 2014 Dec; 6(12):5583-99. PubMed ID: 25479248
[TBL] [Abstract][Full Text] [Related]
23. The role of immune mechanisms in alcoholic and nonalcoholic steatohepatitis: a 2015 update.
Sutti S; Bruzzì S; Albano E
Expert Rev Gastroenterol Hepatol; 2016; 10(2):243-53. PubMed ID: 26634783
[TBL] [Abstract][Full Text] [Related]
24. Increased circulating zonulin in children with biopsy-proven nonalcoholic fatty liver disease.
Pacifico L; Bonci E; Marandola L; Romaggioli S; Bascetta S; Chiesa C
World J Gastroenterol; 2014 Dec; 20(45):17107-14. PubMed ID: 25493023
[TBL] [Abstract][Full Text] [Related]
25. Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?
Asrih M; Jornayvaz FR
Mol Cell Endocrinol; 2015 Dec; 418 Pt 1():55-65. PubMed ID: 25724480
[TBL] [Abstract][Full Text] [Related]
26. A case-control study of obstructive sleep apnea-hypopnea syndrome in obese and nonobese chinese children.
Xu Z; Jiaqing A; Yuchuan L; Shen K
Chest; 2008 Mar; 133(3):684-9. PubMed ID: 18198258
[TBL] [Abstract][Full Text] [Related]
27. Characterization of lean patients with nonalcoholic fatty liver disease: potential role of high hemoglobin levels.
Akyuz U; Yesil A; Yilmaz Y
Scand J Gastroenterol; 2015 Mar; 50(3):341-6. PubMed ID: 25540973
[TBL] [Abstract][Full Text] [Related]
28. Developmental Origins of Nonalcoholic Fatty Liver Disease (NAFLD).
Itoh H; Kanayama N
Adv Exp Med Biol; 2018; 1012():29-39. PubMed ID: 29956192
[TBL] [Abstract][Full Text] [Related]
29. Exosome and Macrophage Crosstalk in Sleep-Disordered Breathing-Induced Metabolic Dysfunction.
Khalyfa A; Kheirandish-Gozal L; Gozal D
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30380647
[TBL] [Abstract][Full Text] [Related]
30. Chemokine ligand 2 and paraoxonase-1 in non-alcoholic fatty liver disease: The search for alternative causative factors.
Camps J; Joven J
World J Gastroenterol; 2015 Mar; 21(10):2875-82. PubMed ID: 25780284
[TBL] [Abstract][Full Text] [Related]
31. Treatment of experimental non-alcoholic steatohepatitis by targeting α7 nicotinic acetylcholine receptor-mediated inflammatory responses in mice.
Zhou Z; Liu YC; Chen XM; Li FQ; Tong XJ; Ding YP; Tang CL
Mol Med Rep; 2015 Nov; 12(5):6925-31. PubMed ID: 26397391
[TBL] [Abstract][Full Text] [Related]
32. Pharyngeal constrictor muscle fatty change may contribute to obstructive sleep apnea-hypopnea syndrome: a prospective observational study.
Shi L; Wang H; Wei L; Hong Z; Wang M; Wang Z
Acta Otolaryngol; 2016 Dec; 136(12):1285-1290. PubMed ID: 27399965
[TBL] [Abstract][Full Text] [Related]
33. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
Streba LA; Vere CC; Rogoveanu I; Streba CT
World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
[TBL] [Abstract][Full Text] [Related]
34. Bergamot polyphenol fraction prevents nonalcoholic fatty liver disease via stimulation of lipophagy in cafeteria diet-induced rat model of metabolic syndrome.
Parafati M; Lascala A; Morittu VM; Trimboli F; Rizzuto A; Brunelli E; Coscarelli F; Costa N; Britti D; Ehrlich J; Isidoro C; Mollace V; Janda E
J Nutr Biochem; 2015 Sep; 26(9):938-48. PubMed ID: 26025327
[TBL] [Abstract][Full Text] [Related]
35. Obesity, fatty liver disease and intestinal microbiota.
Arslan N
World J Gastroenterol; 2014 Nov; 20(44):16452-63. PubMed ID: 25469013
[TBL] [Abstract][Full Text] [Related]
36. An experimental research on chronic intermittent hypoxia leading to liver injury.
Feng SZ; Tian JL; Zhang Q; Wang H; Sun N; Zhang Y; Chen BY
Sleep Breath; 2011 Sep; 15(3):493-502. PubMed ID: 20582634
[TBL] [Abstract][Full Text] [Related]
37. Obstructive Sleep Apnea Is Associated with Liver Damage and Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease.
Petta S; Marrone O; Torres D; Buttacavoli M; Cammà C; Di Marco V; Licata A; Lo Bue A; Parrinello G; Pinto A; Salvaggio A; Tuttolomondo A; Craxì A; Bonsignore MR
PLoS One; 2015; 10(12):e0142210. PubMed ID: 26672595
[TBL] [Abstract][Full Text] [Related]
38. Nutrigenomics analysis reveals that copper deficiency and dietary sucrose up-regulate inflammation, fibrosis and lipogenic pathways in a mature rat model of nonalcoholic fatty liver disease.
Tallino S; Duffy M; Ralle M; Cortés MP; Latorre M; Burkhead JL
J Nutr Biochem; 2015 Oct; 26(10):996-1006. PubMed ID: 26033743
[TBL] [Abstract][Full Text] [Related]
39. Innate Immune Signaling in Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases.
Cai J; Xu M; Zhang X; Li H
Annu Rev Pathol; 2019 Jan; 14():153-184. PubMed ID: 30230967
[TBL] [Abstract][Full Text] [Related]
40. Role of Innate Immune Signaling in Non-Alcoholic Fatty Liver Disease.
Cai J; Zhang XJ; Li H
Trends Endocrinol Metab; 2018 Oct; 29(10):712-722. PubMed ID: 30131212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
